Weekly Investment Analysts’ Ratings Changes for DexCom (DXCM)

A number of firms have modified their ratings and price targets on shares of DexCom (NASDAQ: DXCM) recently:

• 8/11/2026 – DexCom was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/4/2026 – DexCom had its price target raised by Argus from $86.00 to $96.00. They now have a “buy” rating on the stock.
• 8/3/2026 – DexCom was given a new $90.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 7/31/2026 – DexCom had its “buy” rating reaffirmed by TD Cowen.
• 7/31/2026 – DexCom had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $94.00 price target on the stock.
• 7/31/2026 – DexCom had its “overweight” rating reaffirmed by Piper Sandler. They now have a $95.00 price target on the stock, up from $88.00.
• 7/31/2026 – DexCom was given a new $105.00 price target by Robert W. Baird.
• 7/31/2026 – DexCom had its “buy” rating reaffirmed by Citigroup Inc.. They now have a $88.00 price target on the stock, up from $84.00.
• 7/31/2026 – DexCom had its “buy” rating reaffirmed by BTIG Research. They now have a $90.00 price target on the stock, up from $80.00.
• 7/31/2026 – DexCom was given a new $93.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
• 7/31/2026 – DexCom was given a new $95.00 price target by Stifel Nicolaus. They now have a “buy” rating on the stock.
• 7/31/2026 – DexCom had its price target raised by Royal Bank Of Canada from $85.00 to $90.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – DexCom had its price target raised by Mizuho from $90.00 to $95.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – DexCom had its price target raised by JPMorgan Chase & Co. from $65.00 to $82.00. They now have a “neutral” rating on the stock.
• 7/31/2026 – DexCom had its price target raised by Wells Fargo & Company from $85.00 to $90.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – DexCom had its price target raised by Benchmark Co. from $77.00 to $82.00. They now have a “buy” rating on the stock.
• 7/28/2026 – DexCom was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 7/28/2026 – DexCom was given a new $96.00 price target by UBS Group AG. They now have a “buy” rating on the stock.
• 7/28/2026 – DexCom had its “buy” rating reaffirmed by UBS Group AG. They now have a $96.00 price target on the stock.
• 7/16/2026 – DexCom had its price target raised by Truist Financial Corporation from $80.00 to $87.00. They now have a “buy” rating on the stock.
• 7/15/2026 – DexCom had its price target raised by Mizuho from $85.00 to $90.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – DexCom was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 6/23/2026 – DexCom had its “buy” rating reaffirmed by Benchmark Co..
• 6/23/2026 – DexCom is now covered by Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $86.00 price target on the stock.

Insiders Place Their Bets

In related news, Director Mark G. Foletta sold 4,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director directly owned 52,852 shares in the company, valued at $3,917,918.76. The trade was a 7.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 99,794 shares of company stock valued at $7,373,321. Company insiders own 0.28% of the company’s stock.

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.